APPLICATION
ANDA090385
TYPE
ANDA
ORIGINAL APPROVAL
2011-02-24
LATEST ACTION
2025-07-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
LEVOCETIRIZINE DIHYDROCHLORIDEPrescription
LEVOCETIRIZINE DIHYDROCHLORIDE 5MG · TABLET · ORAL
Approval history
2025-07-11Labeling · Supplement 18 · standardAP
2020-11-05Labeling · Supplement 12 · standardAP
2018-06-27Labeling · Supplement 9 · standardAP
2018-06-27Labeling · Supplement 7 · standardAP
2018-06-27Labeling · Supplement 5 · standardAP
2018-06-27Labeling · Supplement 8 · standardAP
2018-06-27Labeling · Supplement 6 · standardAP
2015-11-25Labeling · Supplement 4 · standardAP
2013-11-29Labeling · Supplement 3 · standardAP
2013-02-05Labeling · Supplement 2 · standardAP
2011-02-24OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.